BARDA Scales Up COVID-19 Vaccine Manufacturing Capacity With $628m For Emergent BioSolutions

 
• By Bowman Cox

An inflection point arrives as US public sector pharma manufacturing hits 'warp speed' in COVID-19 crisis.

Pharmaceutical manufacturer of vaccines, discovery of the right drug to fight a disease. Vaccine, protection campaign, health. Diseases and cures. 3d rendering. Immunity against diseases
Vaccine capacity secured at warp speed • Source: Shutterstock

More from Vaccines

More from Pink Sheet